Cover ImageSALE
市場調查報告書

帕金森氏症 (PD) 治療藥的全球市場:2017∼2021年

Global Parkinson's Disease (PD) Drugs Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 547872
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
帕金森氏症 (PD) 治療藥的全球市場:2017∼2021年 Global Parkinson's Disease (PD) Drugs Market 2017-2021
出版日期: 2017年08月18日 內容資訊: 英文 85 Pages
簡介

帕金森氏症 (PD) 是進行性的神經退化性疾病,腦內各處 (包含腦黑質)的多巴胺工作性神經受到損傷,使紋狀體的多巴胺濃度減少80%,而產生震顫 、行動緩慢、肌肉僵硬的症狀。主要是50歲以上之後發病,不過,也有早期發病的案例報告。全球帕金森氏症治療藥市場,預計2017∼2021年以3.81%的年複合成長率成長。

本報告提供全球帕金森氏症 (PD) 用治療藥的市場相關分析,疾病概要和市場基本結構,臨床實驗的進展 (產品平台),市場規模趨勢 (今後5年的預測值),各類藥物、各地區的詳細趨勢,推動、市場的阻礙要素與其影響力,主要企業簡介等調查。

第1章 摘要整理

第2章 分析範圍

第3章 市場分析技術

第4章 簡介

  • 市場概要

第5章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第6章 開發平台環境

第7章 各類藥物的市場區隔

  • 多巴胺促效劑
  • MAO (單胺氧化酵素) 抑制劑
  • AChE (乙醯膽鹼酯化酶) 抑制劑
  • 麩胺酸抑制劑
  • 其他

第8章 各地區的市場區隔

  • 南北美洲
  • 歐洲、中東、非洲各國 (EMEA)
  • 亞太地區

第9章 決策組成架構

第10章 推動因素與課題

  • 市場的推動要素
  • 市場課題

第11章 市場趨勢

  • 生物標記的登場
  • 為了反轉帕金森氏症進展的基因治療
  • 生物醫學的進步
  • 對精神疾病再生醫療的關注
  • 單株抗體 (mAb)的急速成長可能性

第12章 供應商環境

  • 競爭方案
  • 近幾年趨勢

第13章 主要供應商分析

  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical Industries
  • 其他卓越供應商

第14章 附錄

  • 簡稱集

圖表一覽

目錄
Product Code: IRTNTR14672

About Parkinson's Disease (PD) Drugs

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra. This lowers the concentration of dopamine in the striatum by 80%. This decrease in dopamine levels leads to symptoms associated with PD such as tremors, bradykinesia, and muscular rigidity. It is usually diagnosed after the age of 50 years; however, cases of earlier incidence have also been reported.

Technavio's analysts forecast the global parkinson's disease (PD) drugs market to grow at a CAGR of 3.81% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global parkinson's disease (PD) drugs market for 2017-2021. To calculate the market size, the report considers sales/revenues and market share of the PD drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Parkinson's Disease (PD) Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical Industries

Other Prominent Vendors

  • AbbVie
  • Abital Pharma
  • Addex Therapeutics
  • Biogen
  • Eisai
  • Eli Lilly
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Impax Laboratories
  • Kyowa Hakko Kirin
  • Otsuka Pharmaceutical
  • Pfizer
  • Prana Biotechnology
  • Reviva Pharmaceuticals
  • SK Biopharmaceuticals
  • Takeda Pharmaceutical
  • UCB

Market driver

  • Rise in geriatric population
  • For a full, detailed list, view our report

Market challenge

  • Entry of generics
  • For a full, detailed list, view our report

Market trend

  • Emergence of biomarkers
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation by drug class

  • Dopamine agonist
  • MAO inhibitors
  • AChE inhibitors
  • Glutamate inhibitors
  • Others

PART 08: Market segmentation based on geography

  • PD drugs market in Americas
  • PD drugs market in EMEA
  • PD drugs market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges

  • Market drivers
  • Market challenges

PART 11: Market trends

  • Emergence of biomarkers
  • Gene therapy to reverse the progression of PD
  • Advancing biomedical science
  • Focus on regenerative therapies for mental disorders
  • High growth potential of mAbs

PART 12: Vendor landscape

  • Competitive scenario
  • Key news

PART 13: Key vendor analysis

  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical Industries
  • Other prominent vendors

PART 14: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global PD drugs market: A snapshot
  • Exhibit 02: Global PD drugs market 2016-2021 ($ millions)
  • Exhibit 03: Opportunity analysis of global PD drugs market
  • Exhibit 04: Five forces analysis
  • Exhibit 05: Pipeline landscape based on number of molecules, 2016
  • Exhibit 06: Key clinical trials
  • Exhibit 07: Segmentation of global PD drugs market by drug class 2016
  • Exhibit 08: Global PD drugs market share by drug class 2016
  • Exhibit 09: Global PD dopamine agonist drugs market 2016-2021 ($ millions)
  • Exhibit 10: Global PD MAO inhibitors drugs market 2016-2021 ($ millions)
  • Exhibit 11: Global PD AchE inhibitors drugs market 2016-2021 ($ millions)
  • Exhibit 12: Global PD glutamate inhibitors drugs market 2016-2021 ($ millions)
  • Exhibit 13: Segmentation of global PD drugs market share by geography 2016 and 2021 (%)
  • Exhibit 14: Global PD drugs market revenue by geography 2016-2021 ($ millions)
  • Exhibit 15: Global PD drugs market share by geography 2016-2021 (%)
  • Exhibit 16: PD drugs market scenario in different regions
  • Exhibit 17: Market scenario in Americas
  • Exhibit 18: PD drugs market in Americas 2016-2021 ($ millions)
  • Exhibit 19: Market scenario in EMEA
  • Exhibit 20: PD drugs market in EMEA 2016-2021 ($ millions)
  • Exhibit 21: Market scenario in APAC
  • Exhibit 22: PD drugs market in APAC 2016-2021 ($ millions)
  • Exhibit 23: Geriatric population analysis and estimates in 2000 and 2030 (millions)
  • Exhibit 24: Revenue erosion of PD drugs after loss of exclusivity
  • Exhibit 25: Planned clinical trials of iPS cell-based therapies
  • Exhibit 26: Competitive structure analysis of global PD drugs market 2016
  • Exhibit 27: Boehringer Ingelheim: Key highlights
  • Exhibit 28: Boehringer Ingelheim: Strength assessment
  • Exhibit 29: Boehringer Ingelheim: Strategy assessment
  • Exhibit 30: Boehringer Ingelheim: Opportunity assessment
  • Exhibit 31: GlaxoSmithKline: Key highlights
  • Exhibit 32: GlaxoSmithKline: Strength assessment
  • Exhibit 33: GlaxoSmithKline: Strategy assessment
  • Exhibit 34: GlaxoSmithKline: Opportunity assessment
  • Exhibit 35: Novartis: Key highlights
  • Exhibit 36: Novartis: Strength assessment
  • Exhibit 37: Novartis: Strategy assessment
  • Exhibit 38: Novartis: Opportunity assessment
  • Exhibit 39: Teva Pharmaceutical Industries: Key highlights
  • Exhibit 40: Teva Pharmaceutical Industries: Strength assessment
  • Exhibit 41: Teva Pharmaceutical Industries: Strategy assessment
  • Exhibit 42: Teva Pharmaceutical Industries: Opportunity assessment
Back to Top